Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics

  • Xiaowei Zang
  • Leonid KaganEmail author
Original Paper


The objective was to develop a physiologically-based pharmacokinetic (PBPK) model to characterize the whole-body disposition of paclitaxel (formulated in Cremophor EL and ethanol—Taxol®) in mice and to evaluate the utility of this model for predicting pharmacokinetics in other species. Published studies that reported paclitaxel plasma and tissue concentration–time data following single intravenous bolus administration of Taxol® to mice were used; and the PBPK model included plasma, liver, lungs, kidneys, spleen, heart, gastrointestinal tract, and remainder compartments. The final model resulted in a good description of the experimental plasma and tissues data in mice, where all tissues were represented by a single compartment, except the remainder that included two sub-compartments. The predictive performance of the PBPK model was assessed by evaluating its utility in predicting pharmacokinetics of paclitaxel in rats and humans. The relationship between species body weights (mice, rats, rabbits, and humans) and plasma clearance was determined by power-based regression, and resulting allometric exponent was 0.86. The model demonstrated reasonable predictions of plasma and tissue paclitaxel concentration–time profiles in rats and plasma profiles in humans. The proposed PBPK model represents an important basis that can be further utilized for characterization of novel formulations of paclitaxel.


Allometric scaling Taxol Tissue distribution Modeling and simulation 



This work was supported in part by the R01 grant (CA209818) from the National Institute of Health. The authors would like to thank Dr. Luigi Brunetti, Dr. Helene Chapy, Ms. Manting Chiang, and Ms. Xizhe Gao for their insightful comments.


  1. 1.
    Rowinsky EK, Donehower RC (1993) The clinical pharmacology of paclitaxel (Taxol). Semin Oncol 20(4 Suppl 3):16–25PubMedGoogle Scholar
  2. 2.
    Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93(9):2325–2327CrossRefPubMedGoogle Scholar
  3. 3.
    Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82(15):1247–1259CrossRefPubMedGoogle Scholar
  4. 4.
    Schiff PB, Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 77(3):1561–1565CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hamel E, del Campo AA, Lowe MC, Lin CM (1981) Interactions of taxol, microtubule-associated proteins, and guanine nucleotides in tubulin polymerization. J Biol Chem 256(22):11887–11894PubMedGoogle Scholar
  6. 6.
    Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277(5698):665–667CrossRefPubMedGoogle Scholar
  7. 7.
    Wang TH, Wang HS, Soong YK (2000) Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88(11):2619–2628CrossRefPubMedGoogle Scholar
  8. 8.
    Tarr BD, Yalkowsky SH (1987) A new parenteral vehicle for the administration of some poorly water soluble anti-cancer drugs. J Parenter Sci Technol 41(1):31–33PubMedGoogle Scholar
  9. 9.
    Swindell CS, Krauss NE, Horwitz SB, Ringel I (1991) Biologically active taxol analogues with deleted A-ring side chain substituents and variable C-2′ configurations. J Med Chem 34(3):1176–1184CrossRefPubMedGoogle Scholar
  10. 10.
    Ringel I, Horwitz SB (1991) Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83(4):288–291CrossRefPubMedGoogle Scholar
  11. 11.
    Mathew AE, Mejillano MR, Nath JP, Himes RH, Stella VJ (1992) Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. J Med Chem 35(1):145–151CrossRefPubMedGoogle Scholar
  12. 12.
    Lexi-Comp, Inc. Accessed 29 Jan 2017Google Scholar
  13. 13.
    Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F (2000) Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res 887(2):239–249CrossRefPubMedGoogle Scholar
  14. 14.
    Saif MW, Podoltsev NA, Rubin MS, Figueroa JA, Lee MY, Kwon J, Rowen E, Yu J, Kerr RO (2010) Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest 28(2):186–194. CrossRefPubMedGoogle Scholar
  15. 15.
    Jing S, Qiang Z (2015) Advances in the formulation and delivery technology of paclitaxel for injection. J Chin Pharm Sci. CrossRefGoogle Scholar
  16. 16.
    Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803. CrossRefPubMedGoogle Scholar
  17. 17.
    Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP (1987) Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 5(8):1232–1239. CrossRefPubMedGoogle Scholar
  18. 18.
    Rizzo J, Riley C, von Hoff D, Kuhn J, Phillips J, Brown T (1990) Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics. J Pharm Biomed Anal 8(2):159–164CrossRefPubMedGoogle Scholar
  19. 19.
    Walle T, Walle UK, Kumar GN, Bhalla KN (1995) Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 23(4):506–512PubMedGoogle Scholar
  20. 20.
    Gianni L, Kearns CM, Capri G, Vigano L, Locatelli A, Bonadonna G, Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13(1):180–190CrossRefPubMedGoogle Scholar
  21. 21.
    Karlsson MO, Monlnar V, Freijs A, Nygren P, Bergh J, Larsson R (1999) Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos 27(10):1220–1223PubMedGoogle Scholar
  22. 22.
    Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom A (2001) Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 19(20):4065–4073CrossRefPubMedGoogle Scholar
  23. 23.
    Rowland M, Peck C, Tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:45–73. CrossRefPubMedGoogle Scholar
  24. 24.
    Shin BS, Kim HJ, Hong SH, Lee JB, Hwang SW, Lee MH, Yoo SD (2009) Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form. Cancer Chemother Pharmacol 64(1):87–94. CrossRefPubMedGoogle Scholar
  25. 25.
    Gong C, Xie Y, Wu Q, Wang Y, Deng S, Xiong D, Liu L, Xiang M, Qian Z, Wei Y (2012) Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. Nanoscale 4(19):6004–6017. CrossRefPubMedGoogle Scholar
  26. 26.
    Li S, Su Z, Sun M, Xiao Y, Cao F, Huang A, Li H, Ping Q, Zhang C (2012) An arginine derivative contained nanostructure lipid carriers with pH-sensitive membranolytic capability for lysosomolytic anti-cancer drug delivery. Int J Pharm 436(1–2):248–257. CrossRefPubMedGoogle Scholar
  27. 27.
    Yang XY, Li YX, Li M, Zhang L, Feng LX, Zhang N (2013) Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett 334(2):338–345. CrossRefPubMedGoogle Scholar
  28. 28.
    Gu G, Xia H, Hu Q, Liu Z, Jiang M, Kang T, Miao D, Tu Y, Pang Z, Song Q, Yao L, Chen H, Gao X, Chen J (2013) PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials 34(1):196–208. CrossRefPubMedGoogle Scholar
  29. 29.
    Wang Y, Wang C, Gong C, Wang Y, Guo G, Luo F, Qian Z (2012) Polysorbate 80 coated poly (varepsilon-caprolactone)-poly (ethylene glycol)-poly (varepsilon-caprolactone) micelles for paclitaxel delivery. Int J Pharm 434(1–2):1–8. PubMedCrossRefGoogle Scholar
  30. 30.
    Zhang W, Shi Y, Chen Y, Yu S, Hao J, Luo J, Sha X, Fang X (2010) Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur J Pharm Biopharm 75(3):341–353. CrossRefPubMedGoogle Scholar
  31. 31.
    Han LM, Guo J, Zhang LJ, Wang QS, Fang XL (2006) Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123. Acta Pharmacol Sin 27(6):747–753. CrossRefPubMedGoogle Scholar
  32. 32.
    Tong X, Zhou J, Tan Y (2006) Liquid chromatography/tandem triple-quadrupole mass spectrometry for determination of paclitaxel in rat tissues. Rapid Commun Mass Spectrom 20(12):1905–1912. CrossRefPubMedGoogle Scholar
  33. 33.
    Wang Y, Li Y, Wang Q, Wu J, Fang X (2008) Pharmacokinetics and biodistribution of pacliatxel-loaded pluronic P105/L101 mixed polymeric micelles. Yakugaku Zasshi 128(6):941–950CrossRefPubMedGoogle Scholar
  34. 34.
    Peltier S, Oger JM, Lagarce F, Couet W, Benoit JP (2006) Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res 23(6):1243–1250. CrossRefPubMedGoogle Scholar
  35. 35.
    Lee SW, Chang DH, Shim MS, Kim BO, Kim SO, Seo MH (2007) Ionically fixed polymeric nanoparticles as a novel drug carrier. Pharm Res 24(8):1508–1516. CrossRefPubMedGoogle Scholar
  36. 36.
    Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, Kim DD (2007) Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 120(3):169–177. CrossRefPubMedGoogle Scholar
  37. 37.
    Forrest ML, Yanez JA, Remsberg CM, Ohgami Y, Kwon GS, Davies NM (2008) Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity. Pharm Res 25(1):194–206. CrossRefPubMedGoogle Scholar
  38. 38.
    Nornoo AO, Chow DS (2008) Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. Int J Pharm 349(1–2):117–123. CrossRefPubMedGoogle Scholar
  39. 39.
    Zhang Z, Lee SH, Gan CW, Feng SS (2008) In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm Res 25(8):1925–1935. CrossRefPubMedGoogle Scholar
  40. 40.
    Zhang C, Qu G, Sun Y, Wu X, Yao Z, Guo Q, Ding Q, Yuan S, Shen Z, Ping Q, Zhou H (2008) Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials 29(9):1233–1241. CrossRefPubMedGoogle Scholar
  41. 41.
    Gelderblom H, Verweij J, van Zomeren DM, Ouwens L, Nooter K, Stoter G, Sparreboom A (2002) Influence of Cremophor EL on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res 8(4):1237–1241PubMedGoogle Scholar
  42. 42.
    Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (2009) Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemother Pharmacol 63(6):1049–1063. CrossRefPubMedGoogle Scholar
  43. 43.
    Gardner ER, Dahut W, Figg WD (2008) Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment. J Chromatogr B Analyt Technol Biomed Life Sci 862(1–2):213–218. CrossRefPubMedGoogle Scholar
  44. 44.
    Chen KJ, Chen WY, Chen X, Jia YM, Peng GQ, Chen L (2014) Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study. Eur J Drug Metab Pharmacokinet 39(1):25–31. CrossRefPubMedGoogle Scholar
  45. 45.
    Veltkamp SA, Thijssen B, Garrigue JS, Lambert G, Lallemand F, Binlich F, Huitema AD, Nuijen B, Nol A, Beijnen JH, Schellens JH (2006) A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br J Cancer 95(6):729–734. CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Gerlowski LE, Jain RK (1983) Physiologically based pharmacokinetic modeling: principles and application. J Pharm Sci 72(10):1103–1127CrossRefPubMedGoogle Scholar
  47. 47.
    Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10(7):1093–1095CrossRefPubMedGoogle Scholar
  48. 48.
    Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407–484CrossRefPubMedGoogle Scholar
  49. 49.
    Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker Inc, New YorkGoogle Scholar
  50. 50.
    Bissery MC, Nohynek G, Sanderink GJ, Lavelle F (1995) Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 6 (3):339-355; 363-338Google Scholar
  51. 51.
    Eiseman JL, Eddington ND, Leslie J, MacAuley C, Sentz DL, Zuhowski M, Kujawa JM, Young D, Egorin MJ (1994) Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 34(6):465–471CrossRefPubMedGoogle Scholar
  52. 52.
    Fetterly GJ, Straubinger RM (2003) Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSci 5(4):E32CrossRefPubMedGoogle Scholar
  53. 53.
    Sparreboom A, Van Tellingen O, Nooijen WJ, Beijnen J (1998) Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 9(1):1–17CrossRefPubMedGoogle Scholar
  54. 54.
    Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1996) Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs 7(1):78–86CrossRefPubMedGoogle Scholar
  55. 55.
    Walle T, Kumar GN, McMillan JM, Thornburg KR, Walle UK (1993) Taxol metabolism in rat hepatocytes. Biochem Pharmacol 46(9):1661–1664CrossRefPubMedGoogle Scholar
  56. 56.
    Monsarrat B, Royer I, Wright M, Cresteil T (1997) Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. Bull Cancer 84(2):125–133PubMedGoogle Scholar
  57. 57.
    Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijier DK, Borst P, Nooijen WJ, Beijnen JH, Van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 94(5):2031–2035CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Kagan L, Gershkovich P, Wasan KM, Mager DE (2011) Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone(R)): pooled analysis of published data. AAPS J 13(2):255–264. CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Kagan L, Gershkovich P, Wasan KM, Mager DE (2014) Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition. Pharm Res 31(1):35–45. CrossRefPubMedGoogle Scholar
  60. 60.
    Kawai R, Lemaire M, Steimer JL, Bruelisauer A, Niederberger W, Rowland M (1994) Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokinet Biopharm 22(5):327–365CrossRefPubMedGoogle Scholar
  61. 61.
    Wei Y, Xue Z, Ye Y, Wang P, Huang Y, Zhao L (2014) Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation. Biomed Chromatogr 28(2):204–212. CrossRefPubMedGoogle Scholar
  62. 62.
    Ait-Oudhia S, Straubinger RM, Mager DE (2012) Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. Pharm Res 29(10):2833–2844. CrossRefPubMedGoogle Scholar
  63. 63.
    TAXOL® (paclitaxel) INJECTION [package insert] (2011) Bristol-Myers Squibb CompanyGoogle Scholar
  64. 64.
    Rowinsky EK, Jiroutek M, Bonomi P, Johnson D, Baker SD (1999) Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res 5(4):767–774PubMedGoogle Scholar
  65. 65.
    Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB (1993) Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 68(6):1104–1109CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Pushkarev VM, Starenki DV, Saenko VA, Yamashita S, Kovzun OI, Popadiuk ID, Pushkarev VV, Tronko MD (2009) Effects of low and high concentrations of antitumour drug taxol in anaplastic thyroid cancer cells. Exp Oncol 31(1):16–21PubMedGoogle Scholar
  67. 67.
    Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Fety R, Van der Vijgh WJ, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH (2007) Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 13(21):6410–6418. CrossRefPubMedGoogle Scholar
  68. 68.
    Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC (1993) Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 15:107–115Google Scholar
  69. 69.
    Polomano RC, Mannes AJ, Clark US, Bennett GJ (2001) A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 94(3):293–304CrossRefPubMedGoogle Scholar
  70. 70.
    Lee JB, Zgair A, Taha DA, Zang X, Kagan L, Kim TH, Kim MG, Yun HY, Fischer PM, Gershkovich P (2017) Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays. Eur J Pharm Biopharm. CrossRefPubMedGoogle Scholar
  71. 71.
    Straubinger RM (1995) Biopharmaceutics of paclitaxel (Taxol): formulation, activity, and pharmacokinetics. In: M. S (ed) Taxol: Science and Applications, vol 22. Pharmacology and Toxicology: Basic and Clinical Aspects, illustrated edn. CRC Press, Boca Raton, p 448Google Scholar
  72. 72.
    Waugh WN, Trissel LA, Stella VJ (1991) Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm 48(7):1520–1524PubMedGoogle Scholar
  73. 73.
    Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R (1993) Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 15:141–147Google Scholar
  74. 74.
    Song D, Hsu LF, Au JL (1996) Binding of taxol to plastic and glass containers and protein under in vitro conditions. J Pharm Sci 85(1):29–31CrossRefPubMedGoogle Scholar
  75. 75.
    Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV (1994) Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12(3):532–538. CrossRefPubMedGoogle Scholar
  76. 76.
    Sparreboom A, Van Tellingen O, Nooijen WJ, Beijnen JH (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56(9):2112–2115PubMedGoogle Scholar
  77. 77.
    Van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH (1999) Cremophor EL causes (pseudo-) non-linear pharmacokineitcs of paclitaxel in patients. Br J Cancer 81(2):330–335CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Cao Y, Jusko WJ (2012) Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn 39(6):711–723. CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Lu XF, Bi K, Chen X (2016) Physiologically based pharmacokinetic model of docetaxel and interspecies scaling: comparison of simple injection with folate receptor-targeting amphiphilic copolymer-modified liposomes. Xenobiotica 46(12):1093–1104. CrossRefPubMedGoogle Scholar
  80. 80.
    Kawai R, Mathew D, Tanaka C, Rowland M (1998) Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J Pharmacol Exp Ther 287(2):457–468PubMedGoogle Scholar
  81. 81.
    Tang H, Mayersohn M (2006) A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci 95(8):1783–1799. CrossRefPubMedGoogle Scholar
  82. 82.
    Hu TM, Hayton WL (2001) Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci 3(4):E29CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmaceutics, Ernest Mario School of Pharmacy, RutgersThe State University of New JerseyPiscatawayUSA

Personalised recommendations